TMCnet - World's Largest Communications and Technology Community



Alnylam to Host "RNAi Roundtable" Webcast Series
[July 07, 2014]

Alnylam to Host "RNAi Roundtable" Webcast Series

CAMBRIDGE, Mass. --(Business Wire)--

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it plans to host and webcast a series of online "RNAi Roundtables" during July and August. Alnylam scientists and key clinical collaborators will review recent progress from several of the "Alnylam 5x15" programs and discuss the related disease areas. Each event will be webcast live on the Investors section of the company's website, An audio replay of the roundtables will be posted on the Alnylam website approximately three hours after each event.

The RNAi Roundtable topics scheduled to date include:

Patisiran and ALN-TTRsc for the treatment of Transthyretin-Mediated Amyloidosis (ATTR)

Tuesday, July 15: 12:30 - 2:00 p.m. ET

  • Jared Gollob, M.D., Vice President, Clinical Research
  • Moderator: John Maraganore, Ph.D., Chief Executive Officer
  • Guest Speaker: Philip N. Hawkins, M.B., B.S., Ph.D., FRCP, Professor of Medicine, National Amyloidosis Centre, University College London Medical School

Advances in Delivery of RNAi Therapeutics with Enhanced Stabilization Chemistry (ESC (News - Alert))-GalNAc-siRNA Conjugates

Tuesday, July 22: 11:00 a.m. - 12:00 p.m. ET

  • Rachel Meyers, Ph.D., Vice President, Research and RNAi Lead Development
  • Moderator: Laurence Reid, Ph.D., Senior Vice President and Chief Business Officer

ALN-HBV for the treatment of Hepatitis B Virus (HBV) Infection

Tuesday, July 29: 9:30 - 10:30 a.m. ET

  • Laura Sepp-Lorenzino, Ph.D., Vice President, Entrepreneur-in-Residence
  • Moderator: Laurence Reid, Ph.D., Senior Vice President and Chief Business Officer
  • Guest Speaker: Graham Foster, Ph.D., FRCP, Professor of Hepatology at Queen Mary University of London

ALN-AT3 for the treatment of Hemophilia and Rare Bleeding Disorders

Thursday, August 7: 9:30 - 10:30 a.m. ET

  • Akin Akinc, Ph.D., Director, Research
  • Moderator: John Maraganore, Ph.D., Chief Executive Officer
  • Guest Speaker: Flora Peyvandi, M.D., Ph.D., Head of the Department of Internal Medicine and Angelo Bianchi Bonomi Hemophilia and Thrombosis Centre, IRCCS Maggiore Hospital, University of Milan.

ALN-CC5 for the treatment of Complement-Mediated Diseases

Wednesday, August 13: 9:30 - 10:30 a.m. ET

  • Benny Sorensen, M.D., Ph.D., Medical Director, Clinical Development
  • Moderator: Barry Greene, President and Chief Operating Officer
  • Guest Speaker: Anita Hill, MBChB (Hons), MRCP, FRCPath, Ph.D., Consultant Haematologist for Leeds Teaching Hospitals NHS Trust, UK, and Honorary Senior Lecturer at the University of Leeds

Alnylam plans to schedule additional RNAi Roundtables covering other pipeline programs to take place in the coming weeks, including ALN-AS1 for the treatment of hepatic porphyrias; ALN-PCSsc for the treatment of hypercholesterolemia; and ALN-AAT for the treatment of AAT deficiency-associated liver disease. The topics, dates, and times of these events will be posted on the Capella section of the company's website,

About Alnylam Pharmaceuticals

Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is leading the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics as genetic medicines, including programs as part of the company's "Alnylam 5x15TM" product strategy. Alnylam's genetic medicine programs are RNAi therapeutics directed toward genetically defined targets for the treatment of serious, life-threatening diseases with limited treatment options for patients and their caregivers. These include: patisiran (ALN-TTR02), an intravenously delivered RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR) in patients with familial amyloidotic polyneuropathy (FAP); ALN-TTRsc, a subcutaneously delivered RNAi therapeutic targeting TTR for the treatment of ATTR in patients with TTR cardiac amyloidosis, including familial amyloidotic cardiomyopathy (FAC) and senile systemic amyloidosis (SSA); ALN-AT3, an RNAi therapeutic targeting antithrombin (AT) for the treatment of hemophilia and rare bleeding disorders (RBD); ALN-CC5, an RNAi therapeutic targeting complement component C5 for the treatment of complement-mediated diseases; ALN-AS1, an RNAi therapeutic targeting aminolevulinic acid synthase-1 (ALAS-1) for the treatment of hepatic porphyrias including acute intermittent porphyria (AIP); ALN-PCS, an RNAi therapeutic targeting PCSK9 for the treatment of hypercholesterolemia; ALN-AAT, an RNAi therapeutic targeting alpha-1 antitrypsin (AAT) for the treatment of AAT deficiency-associated liver disease; ALN-TMP, an RNAi therapeutic targeting TMPRSS6 for the treatment of beta-thalassemia and iron-overload disorders; ALN-ANG, an RNAi therapeutic targeting angiopoietin-like 3 (ANGPTL3) for the treatment of genetic forms of mixed hyperlipidemia and severe hypertriglyceridemia; ALN-AC3, an RNAi therapeutic targeting apolipoprotein C-III (apoCIII) for the treatment of hypertriglyceridemia; and other programs yet to be disclosed. As part of its "Alnylam 5x15" strategy, as updated in early 2014, the company expects to have six to seven genetic medicine product candidates in clinical development - including at least two programs in Phase 3 and five to six programs with human proof of concept - by the end of 2015. Alnylam is also developing ALN-HBV, an RNAi therapeutic targeting the hepatitis B virus (HBV) genome for the treatment of HBV infection. The company's demonstrated commitment to RNAi therapeutics has enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, Biogen Idec, Roche, Takeda, Kyowa Hakko Kirin, Cubist, GlaxoSmithKline, Ascletis, Monsanto, The Medicines Company, and Genzyme, a Sanofi company. In March 2014, Alnylam acquired Sirna Therapeutics, a wholly owned subsidiary of Merck. In addition, Alnylam holds an equity position in Regulus Therapeutics Inc., a company focused on discovery, development, and commercialization of microRNA therapeutics. Alnylam scientists and collaborators have published their research on RNAi therapeutics in over 200 peer-reviewed papers, including many in the world's top scientific journals such as Nature, Nature Medicine, Nature Biotechnology, Cell, the New England Journal of Medicine, and The Lancet. Founded in 2002, Alnylam maintains headquarters in Cambridge, Massachusetts. For more information, please visit

[ Back To's Homepage ]

Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments:
Comments about this site:


© 2017 Technology Marketing Corporation. All rights reserved | Privacy Policy